Mass Spectrometry-based Biomarker Discovery for Patient Stratification in Oncology Clinical Trials

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Mass Spectrometry-based Biomarker Discovery for Patient Stratification in Oncology Clinical Trials

Mass Spectrometry Proteomics for Oncology Patient Stratification

CELL & GENE | RNA | BIOLOGICS

Frequently Asked Questions (FAQ)

Technical Question Franklin Biolabs Response
What is the typical sample input requirement for a discovery proteomics study? For plasma or serum, we typically require a minimum of 50-100 µL. For FFPE tissue, we recommend at least three 10 µm scrolls. Requirements are project-specific and optimized during assay development.
How does Franklin Biolabs handle data analysis for large-scale proteomic datasets? We employ a proprietary bioinformatic pipeline that integrates search algorithms with advanced statistical modeling and machine learning to identify and validate candidate biomarker signatures from complex datasets. This is managed within a GxP-compliant framework.
Which mass spectrometry platforms are utilized for biomarker discovery? Our instrumentation suite includes high-resolution Orbitrap platforms and triple-quadrupole mass spectrometers, enabling both deep discovery proteomics (Data-Independent Acquisition) and targeted validation assays (Parallel Reaction Monitoring).
Can this service be integrated with other GxP-compliant bioanalytical assays? Yes. Proteomic data is frequently correlated with our other bioanalytical services, including ligand-binding assays, flow cytometry, and quantitative PCR, to build a comprehensive biological profile for patient stratification.

A scientist in a lab coat and gloves looks through a microscope in a laboratory setting, with a blue color overlay.

A scientist pipetting a red liquid into a multi-well plate in a laboratory setting.

Executive Summary

Mass spectrometry-based proteomics provides a high-throughput, unbiased method for identifying protein expression signatures that correlate with clinical outcomes in oncology. This capability is fundamental for stratifying patient populations, enabling the design of more efficient and successful clinical trials. By quantifying thousands of proteins directly from patient samples (e.g., plasma, tumor tissue), we can develop predictive biomarker panels that identify likely responders versus non-responders before treatment initiation, significantly de-risking development programs. Franklin Biolabs executes these complex discovery and validation studies within a GxP framework, leveraging advanced instrumentation to support your IND submission.

The Challenge of Patient Heterogeneity in Oncology

The efficacy of targeted oncology therapeutics is often confined to specific patient subpopulations. Enrolling a heterogeneous population into a clinical trial without robust stratification biomarkers can mask a strong efficacy signal, leading to trial failure. Identifying a validated, predictive biomarker signature is a primary objective for de-risking a development program and optimizing the path to approval.

Mass spectrometry offers a direct, quantitative view of the proteome, revealing the functional biology that underpins treatment response or resistance. This approach moves beyond genomics to capture the dynamic state of the cellular machinery targeted by your therapeutic.

  • Unbiased Discovery: Screen thousands of proteins simultaneously to identify novel candidate biomarkers without a prior hypothesis.

  • Quantitative Precision: Measure subtle changes in protein abundance between responder and non-responder cohorts.

  • Translational Utility: Develop targeted mass spectrometry assays for clinical validation of discovered biomarker panels.

A female scientist in a lab coat analyzes complex biological data, including cellular imagery and DNA models, on a computer screen.

A senior scientist with grey hair is mentoring a diverse group of younger scientists or students in a laboratory setting.

From Discovery to Clinical Application

The strategic value of defining a therapeutic window and anticipating patient response cannot be overstated. For instance, research into gene therapy dose-finding has shown the importance of identifying a minimally effective threshold to achieve a therapeutic effect (PMID: 34652966). Similarly, proteomic biomarkers help define the molecular threshold for a patient’s likely response to therapy.

Conversely, the history of advanced therapeutics includes cases where unforeseen biological responses in specific patients led to severe adverse events, highlighting the limitations of preclinical models (PMID: 14567964). Proteomic stratification aims to prospectively identify patients with molecular profiles that suggest a higher risk of adverse events, allowing for their exclusion from trials and improving overall program safety. This focus on safety underpins the 100% IND approval success rate our core team has maintained since 2019, a track record of expertise now embodied by the Franklin Biolabs brand, launched in 2024.

A GxP-Compliant Framework for Biomarker Validation

Franklin Biolabs operates within a >100,000 sq ft facility designed for GxP-compliant bioanalysis. Our strategic partnerships with leading instrumentation and software providers ensure access to the most advanced platforms for proteomic analysis. We integrate these powerful discovery tools into a rigorous development framework that supports an 18-24 month IND timeline, translating complex biological data into actionable clinical strategies.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities